Search results
Results from the WOW.Com Content Network
Dapagliflozin is used along with diet, exercise, and usually with other glucose-lowering medications, to improve glycaemic control in adults with type 2 diabetes. . Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when added to the existing treatment
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors ...
For premium support please call: 800-290-4726 more ways to reach us
The number and size of cysts and kidney volume are predictors for the progression of CKD and end-stage renal disease. PKD does not increase the risk for the development of renal cancer, but if such develops, it is more likely to be bilateral. The most probable cause of death is heart disease, ruptured cerebral aneurysm, or disseminated infection.
FDA approves label expansion of Merck's (MRK) Keytruda and J&J's (JNJ) Erleada. Skip to main content. News. 24/7 help. For premium support please call: 800-290-4726 more ways to reach us ...
FDA staff reviewers raised concerns over unclear benefits of Ardelyx's drug for kidney disease patients, but the company's shares are up on expectations over a possible approval.
[1] [24] Studies led by Mayo Clinic professionals established that the total kidney volume (TKV) in a large cohort of ADPKD patients was 1060 ± 642ml with a mean increase of 204ml over three years, or 5.27% per year in the natural course of the disease, among other important, novel findings that were extensively studied for the first time.
The approval is based on a late-stage study in which PiaSky showed a 79.3% control in the destruction of red blood cells versus 79% for the standard-of-care eculizumab from week 5 to week 25.